Using generic imatinib and then switching to other tyrosine kinase inhibitors (TKIs) if intolerance or lack of effectiveness occurs would be the most cost-effective initial treatment strategy to treat chronic-phase chronic myeloid leukemia (CP-CML), according to a multinational team of investigators.
But one expert cautioned that there are still patients for whom a second-generation TKI—dasatinib (Sprycel, Bristol-Myers Squibb) or nilotinib (Tasigna, Novartis)—is a more appropriate